You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Myeloid Leukemia Trial in Germany, Netherlands (TKI discontinuation, nilotinib)

Active, not recruiting
  • Chronic Myeloid Leukemia
  • Freiburg, Baden-Württemberg, Germany
  • +14 more
Nov 4, 2021

Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in France (Ponatinib, Imatinib)

Recruiting
  • Philadelphia Chromosome Positive CML
  • BCR-ABL Positive Chronic Myelogenous Leukemia
  • Amiens, France
  • +27 more
Dec 9, 2021

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Los Angeles, California
  • +31 more
Nov 11, 2021

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)

Recruiting
  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
  • Longmont, Colorado
  • +128 more
Aug 1, 2022

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial

Recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
  • Houston, Texas
  • +3 more
Jan 25, 2022

Chronic Myeloid Leukemia, BCR/ABL-Positive Trial in Taipei

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jul 24, 2022

    Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

    Recruiting
    • Chronic Myelogenous Leukemia
    • ABL001 40mg BID
    • +2 more
    • Caba, Buenos Aires, Argentina
    • +53 more
    Jan 27, 2023

    Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

    Not yet recruiting
    • Chronic Myeloid Leukemia
    • Treatment-free Remission
    • TFR(Treatment-Free Remission)
    • (no location specified)
    Jun 27, 2022

    Nilotinib for Chronic Myeloid Leukemia in First Line and Any

    Completed
    • Chronic Myeloid Leukemia
    • Nilotinib
    • Freudenstadt, Baden Wuerttemberg, Germany
    • +76 more
    Feb 9, 2023

    Generic Imatinib Compared to Glivec® in Real-Life Management of

    Not yet recruiting
    • Chronic Myeloid Leukemia
    • Cairo, Egypt
    • +1 more
    Mar 16, 2022

    Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

    Recruiting
    • Olverembatinib
    • +2 more
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Jul 26, 2022

    Chronic Myeloid Leukemia, Chronic Phase Trial in Beijing (Radotinib, Imatinib)

    Active, not recruiting
    • Chronic Myeloid Leukemia, Chronic Phase
    • Beijing, China
      Peking University People's Hospital(北京大学人民医院)
    Jan 3, 2022

    Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

    Recruiting
    • Philadelphia Chromosome
    • +4 more
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jun 23, 2022

    Chronic Phase Chronic Myeloid Leukemia Trial in Worldwide (Dasatinib)

    Completed
    Has Results
    • Chronic Phase Chronic Myeloid Leukemia
    • Duarte, California
    • +27 more
    Dec 7, 2021

    Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 24, 2022

    Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome Trial

    Completed
    Has Results
    • Chronic Myelogenous Leukemia
    • +3 more
    • Duarte, California
    • +100 more
    Jun 8, 2021

    TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy

    Recruiting
    • Chronic Myeloid Leukemia
    • Pisa, Italy
    • +1 more
    Jan 4, 2022

    Chronic Myeloid Leukemia, Chronic Phase, Nilotinib Trial in Shenzhen (Nilotinib)

    Recruiting
    • Chronic Myeloid Leukemia, Chronic Phase
    • Nilotinib
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Mar 15, 2022

    Leukemia, Myeloid, Chronic-Phase Trial in Germany (Ponatinib)

    Active, not recruiting
    • Leukemia, Myeloid, Chronic-Phase
    • Halle (Saale), Saxony-Anhalt, Germany
    • +9 more
    Sep 9, 2022

    CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

    Recruiting
    • CML, Chronic Phase
    • Flumatinib mesylate tablets (400mg)
    • Flumatinib mesylate tablets (600mg)
    • Harbin, Hei Longjiang, China
      Institute of Hematology and Oncology, Harbin The First Hospital
    Apr 28, 2022

    Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)

    Terminated
    Has Results
    • Chronic Phase Chronic Myeloid Leukemia
    • Ponatinib 30 mg QD
    • +2 more
    • Bruxelles, Belgium
      Cliniques Universitaire Saint-Luc (Site 058)
    Oct 28, 2021

    CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

    Not yet recruiting
    • CML (Chronic Myelogenous Leukemia
    • (no location specified)
    Jul 27, 2022

    Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Canada, United States (Dasatinib, Imatinib Mesylate, Laboratory

    Active, not recruiting
    Has Results
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Burbank, California
    • +340 more
    Jan 28, 2023

    Chronic Myelogenous Leukemia - Chronic Phase Trial (asciminib)

    Recruiting
    • Chronic Myelogenous Leukemia - Chronic Phase
    • Birmingham, Alabama
    • +25 more
    Jan 10, 2023

    Needs of 3L+ CP-CML and With T315I-mutated CML Patients

    Completed
    • Chronic Myeloid Leukemia
    • 3L Therapy
    • T315I
    • Lyon, France
      Novartis Investigative Site
    Nov 9, 2022